PL1664036T3 - Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 - Google Patents

Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4

Info

Publication number
PL1664036T3
PL1664036T3 PL04744319T PL04744319T PL1664036T3 PL 1664036 T3 PL1664036 T3 PL 1664036T3 PL 04744319 T PL04744319 T PL 04744319T PL 04744319 T PL04744319 T PL 04744319T PL 1664036 T3 PL1664036 T3 PL 1664036T3
Authority
PL
Poland
Prior art keywords
agonistic activity
receptor agonistic
benzimidazolone compounds
benzimidazolone
compounds
Prior art date
Application number
PL04744319T
Other languages
English (en)
Inventor
Satoru Iguchi
Yasuhiro Katsu
Hiroki Sone
Chikara Uchida
Takashi Kojima
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PL1664036T3 publication Critical patent/PL1664036T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Cardiology (AREA)
  • Ceramic Engineering (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04744319T 2003-09-03 2004-08-20 Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 PL1664036T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50014403P 2003-09-03 2003-09-03
PCT/IB2004/002741 WO2005021539A1 (en) 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-ht4 receptor agonistic activity
EP04744319A EP1664036B1 (en) 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-ht4 receptor agonistic activity

Publications (1)

Publication Number Publication Date
PL1664036T3 true PL1664036T3 (pl) 2012-04-30

Family

ID=34272920

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04744319T PL1664036T3 (pl) 2003-09-03 2004-08-20 Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4

Country Status (40)

Country Link
US (2) US7776885B2 (pl)
EP (1) EP1664036B1 (pl)
JP (1) JP3983269B1 (pl)
KR (1) KR100738784B1 (pl)
CN (1) CN100482659C (pl)
AP (1) AP2184A (pl)
AR (1) AR045552A1 (pl)
AT (1) ATE539077T1 (pl)
AU (1) AU2004268840B9 (pl)
BR (1) BRPI0414105B8 (pl)
CA (1) CA2537127C (pl)
CR (1) CR8267A (pl)
CY (1) CY1112321T1 (pl)
DK (1) DK1664036T3 (pl)
EA (1) EA009457B1 (pl)
EC (1) ECSP066407A (pl)
ES (1) ES2377484T3 (pl)
GE (1) GEP20084527B (pl)
GT (1) GT200400174A (pl)
HK (1) HK1093338A1 (pl)
HR (1) HRP20120077T1 (pl)
IL (3) IL173705A (pl)
IS (1) IS8289A (pl)
MA (1) MA28021A1 (pl)
MX (1) MXPA06002550A (pl)
NL (1) NL1026959C2 (pl)
NO (1) NO20061519L (pl)
OA (1) OA13248A (pl)
PA (1) PA8610601A1 (pl)
PE (1) PE20050874A1 (pl)
PL (1) PL1664036T3 (pl)
PT (1) PT1664036E (pl)
RS (1) RS20060145A (pl)
SI (1) SI1664036T1 (pl)
TN (1) TNSN06073A1 (pl)
TW (1) TW200510332A (pl)
UA (1) UA86204C2 (pl)
UY (1) UY28496A1 (pl)
WO (1) WO2005021539A1 (pl)
ZA (1) ZA200601324B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
PL1664036T3 (pl) * 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
KR100875558B1 (ko) 2004-06-15 2008-12-23 화이자 인코포레이티드 벤즈이미다졸론 카복실산 유도체
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
ATE441646T1 (de) 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
JP5042028B2 (ja) 2004-11-05 2012-10-03 セラヴァンス, インコーポレーテッド キノリノン−カルボキサミド化合物
ATE469897T1 (de) 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
EP1856110B1 (en) 2005-02-22 2011-06-22 Pfizer Inc. Oxyindole derivatives as 5ht4 receptor agonists
ES2523851T3 (es) 2005-03-02 2014-12-02 Theravance Biopharma R&D Ip, Llc Compuestos de quinolinona como agonistas de los receptores 5-HT4
CA2601458C (en) 2005-03-15 2011-04-26 Pfizer Inc. Benzimidazolone derivatives as cb2 receptor ligands
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7317022B2 (en) * 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
JP5209481B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド M1受容体にて活性を有する化合物および医薬におけるそれらの使用
JP5209479B2 (ja) * 2005-09-30 2013-06-12 グラクソ グループ リミテッド M1受容体にて活性を有するベンゾイミダゾロン類
KR20130091791A (ko) * 2005-09-30 2013-08-19 글락소 그룹 리미티드 M1 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
NZ570190A (en) * 2006-01-24 2011-03-31 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US20080318964A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched eszopiclone
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
WO2011099305A1 (en) * 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US20120143119A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of Serotonin Receptor Antagonists By Microinjection Systems
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
WO2017093890A1 (en) * 2015-11-30 2017-06-08 Piramal Enterprises Limited Clobazam tablet formulation and process for its preparation
CN116507318A (zh) * 2020-10-23 2023-07-28 怡诺安有限公司 包含苯并咪唑衍生物化合物的口服崩解片剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63716A (en) * 1867-04-09 Improved cheery stoner
US3945953A (en) * 1972-04-21 1976-03-23 Ciba-Geigy Corporation ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use
CH566987A5 (pl) * 1972-04-21 1975-09-30 Ciba Geigy Ag
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0522914A1 (fr) * 1991-06-27 1993-01-13 Synthelabo Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
EP0667867A1 (en) * 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
TW252206B (pl) * 1993-09-01 1995-07-21 Philips Electronics Nv
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2001515887A (ja) 1997-09-09 2001-09-25 デュポン ファーマシューティカルズ カンパニー Xa因子の阻害剤としての、ベンゾイミダゾリノン類、ベンゾオキサゾリノン類、ベンゾピペラジノン類、インダノン類、およびそれらの誘導体
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6420410B1 (en) * 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
EP1346994A4 (en) * 2000-12-28 2005-01-19 Mochida Pharm Co Ltd INHIBITORS OF THE CHOLESTEROL BIOSYNTHESIS CONTAINING TRICYCLIC SPIRO COMPOUNDS AS AN ACTIVE SUBSTANCE
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
PL1664036T3 (pl) * 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
KR100875558B1 (ko) * 2004-06-15 2008-12-23 화이자 인코포레이티드 벤즈이미다졸론 카복실산 유도체
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
GEP20084527B (en) 2008-11-10
ZA200601324B (en) 2007-05-30
PA8610601A1 (es) 2005-03-28
CA2537127A1 (en) 2005-03-10
EA009457B1 (ru) 2007-12-28
IL205600A0 (en) 2010-11-30
TW200510332A (en) 2005-03-16
EA200600327A1 (ru) 2006-08-25
CY1112321T1 (el) 2015-12-09
JP3983269B1 (ja) 2007-09-26
US7776885B2 (en) 2010-08-17
DK1664036T3 (da) 2012-02-13
HK1093338A1 (en) 2007-03-02
NL1026959A1 (nl) 2005-03-07
EP1664036B1 (en) 2011-12-28
KR20060087540A (ko) 2006-08-02
CA2537127C (en) 2011-04-05
ECSP066407A (es) 2006-09-18
MA28021A1 (fr) 2006-07-03
CN100482659C (zh) 2009-04-29
AU2004268840B9 (en) 2011-02-03
ATE539077T1 (de) 2012-01-15
NO20061519L (no) 2006-06-01
AR045552A1 (es) 2005-11-02
IL205599A0 (en) 2010-11-30
ES2377484T3 (es) 2012-03-28
WO2005021539A1 (en) 2005-03-10
BRPI0414105A (pt) 2006-11-21
AP2184A (en) 2010-12-02
CN1845922A (zh) 2006-10-11
EP1664036A1 (en) 2006-06-07
HRP20120077T1 (hr) 2012-02-29
PT1664036E (pt) 2012-02-16
AP2006003536A0 (en) 2006-04-30
IL173705A0 (en) 2006-07-05
SI1664036T1 (sl) 2012-03-30
CR8267A (es) 2006-11-21
TNSN06073A1 (en) 2007-10-03
PE20050874A1 (es) 2005-10-26
UY28496A1 (es) 2005-04-29
JP2007533613A (ja) 2007-11-22
MXPA06002550A (es) 2006-06-20
NL1026959C2 (nl) 2006-01-23
GT200400174A (es) 2005-05-02
IL173705A (en) 2013-04-30
OA13248A (en) 2007-01-31
IS8289A (is) 2006-02-09
KR100738784B1 (ko) 2007-07-12
US20100273794A1 (en) 2010-10-28
RS20060145A (en) 2008-06-05
AU2004268840B2 (en) 2010-09-23
BRPI0414105B8 (pt) 2021-05-25
BRPI0414105B1 (pt) 2018-08-14
AU2004268840A1 (en) 2005-03-10
US20050148573A1 (en) 2005-07-07
UA86204C2 (uk) 2009-04-10

Similar Documents

Publication Publication Date Title
IL205600A0 (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
IL174990A0 (en) Compounds having crth2 antagonist activity
HK1099019A1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
AU2002353403A8 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
EP1559422A4 (en) CONTROLLER OF RECEIVER FUNCTION
HK1079451A1 (en) Use of compounds that are effective as selective opiate receptor modulators
AU153030S (en) Holder for showers
GB0325093D0 (en) Fiberglass nonwoven catalyst
NO20013443L (no) Triazolforbindelser med dopamin-D3-reseptoraktivitet
EP1482895A4 (en) AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
GB0306731D0 (en) Activity monitor
IS2897B (is) Efnasambönd sem hamla gegn virkni kalkviðtaka
IL173337A0 (en) Receptor
DE50303910D1 (de) Rinnenschuss
EP1616880A4 (en) LIGAND WITH AGONISTIC ACTIVITY AGAINST A MUTED RECEPTOR
GB0226227D0 (en) Receptors
PT1558259E (pt) Derivados de ureia como antagonistas do receptor de il-8
SG131946A1 (en) Ccr3 receptor antagonists
ZA200804010B (en) Carbamate compounds as 5-HT4 receptor agonists
GB0223399D0 (en) Receptors
GB2402316B (en) Bed for pets
GB0321998D0 (en) Receptor
AU149317S (en) Sanitary ware for pets
AU149648S (en) Shower unit
GB0307100D0 (en) Receptor